Literature DB >> 18308699

Fabp3 as a biomarker of skeletal muscle toxicity in the rat: comparison with conventional biomarkers.

Michael L Pritt1, David Greg Hall, Justin Recknor, Kelly M Credille, Donna D Brown, Nathan P Yumibe, Albert Eric Schultze, David E Watson.   

Abstract

Fatty acid binding protein 3 (Fabp3) has been used as a serological biomarker of cardiac injury, but its utility as a preclinical biomarker of injury to skeletal muscle is not well described. Fabp3 concentrations were determined for tissues from Sprague-Dawley rats and found to occur at highest concentrations in cardiac muscle and in skeletal muscles containing an abundance of type I fibers, such as the soleus muscle. Soleus is also a primary site of skeletal muscle (SKM) injury caused by lipid-lowering peroxisome proliferator-activated receptor alpha (PPAR-alpha) agonists. In rats administered repeat doses of a PPAR-alpha agonist, the kinetics and amplitude of plasma concentrations of Fabp3 were consistent with plasma compound concentrations and histopathology findings of swollen, hyalinized, and fragmented muscle fibers with macrophage infiltration. Immunohistochemical detection of Fabp3 revealed focal depletion of Fabp3 protein from injured SKM fibers which is consistent with increased serum Fabp3 concentrations in treated rats. We then assessed the predictivity of serological Fabp3 for SKM necrosis in short duration toxicology studies. Rats were treated with various doses of 27 different compounds, and the predictivity of serological biomarkers was assessed relative to histology in individual rats and in treatment groups. Under these study conditions, Fabp3 was the most useful individual biomarker based on concordance, sensitivity, positive and negative predictive values, and false negative rate. In addition, the combination of Fabp3 and aspartate aminotransferase (AST) had greater diagnostic value than the conventional combination of creatine kinase-MM isoenzyme (CK) and AST.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18308699     DOI: 10.1093/toxsci/kfn042

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  7 in total

1.  Heart-type fatty acid-binding protein and its relation with morphological changes in rat myocardial damage model induced by isoproterenol.

Authors:  Sabaheta Hasić; Radivoj Jadrić; Esad Cosović; Emina Kiseljaković; Zakira Mornjaković; Mira Winterhalter-Jadrić
Journal:  Bosn J Basic Med Sci       Date:  2011-11       Impact factor: 3.363

2.  Treatment of chemotherapy-induced cachexia with BST204: a multimodal validation study.

Authors:  Hyun Ju Yoo; Dong-Cheol Woo; Jeong Kon Kim; Ho-Jin Kim; Su Jung Kim; Chul-Woong Woo; Sang-Tae Kim; Minju Im; Sun Kyu Park; Jeom-Yong Kim
Journal:  Metabolomics       Date:  2021-03-18       Impact factor: 4.290

3.  Urinary Fatty Acid Binding Protein 3 Has Prognostic Value in Peripheral Artery Disease.

Authors:  Ben Li; Abdelrahman Zamzam; Muzammil H Syed; Niousha Jahanpour; Shubha Jain; Rawand Abdin; Mohammad Qadura
Journal:  Front Cardiovasc Med       Date:  2022-06-20

4.  Application of dynamic topic models to toxicogenomics data.

Authors:  Mikyung Lee; Zhichao Liu; Ruili Huang; Weida Tong
Journal:  BMC Bioinformatics       Date:  2016-10-06       Impact factor: 3.169

5.  Prediction of sarcopenia using a combination of multiple serum biomarkers.

Authors:  Ju Yeon Kwak; Hyeoncheol Hwang; Seon-Kyu Kim; Jeong Yi Choi; Seung-Min Lee; Hyun Bang; Eun-Soo Kwon; Kwang-Pyo Lee; Sun Gun Chung; Ki-Sun Kwon
Journal:  Sci Rep       Date:  2018-06-05       Impact factor: 4.379

6.  Fatty acid binding protein 3 is associated with peripheral arterial disease.

Authors:  Muzammil H Syed; Abdelrahman Zamzam; Hamzah Khan; Krishna Singh; Thomas L Forbes; Ori Rotstein; Rawand Abdin; John Eikelboom; Mohammad Qadura
Journal:  JVS Vasc Sci       Date:  2020-09-02

7.  Protective Effects of Dexmedetomidine and Oxycodone in Patients Undergoing Limb Ischemia-Reperfusion.

Authors:  Wenjie Cheng; Mingjie Wang; Peng Liu; Shuang Zhao; Xin Liu; Xiuli Wang
Journal:  Med Sci Monit       Date:  2019-11-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.